Non-transferrin bound labile plasma iron and iron overload in sickle cell disease: A comparative study between sickle cell disease and β thalassemic patients

European Journal of Haematology

Volumn 84, Issue 1, 2010, Pages 72-78

  Koren, Ariel ^a,b   Fink, Daniel ^a   Admoni, Osnat ^a   Tennenbaum Rakover, Yardena ^a,b   Levin, Carina ^a,b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Iron overload; Non transferrin bound iron; Sickle cell anemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; HEMOGLOBIN; IRON; NON TRANSFERRIN BOUND IRON; TRANSFERRIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHILD; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SICKLE CELL ANEMIA; SPLENECTOMY; THALASSEMIA; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; COHORT STUDIES; COMORBIDITY; ENDOCRINE SYSTEM DISEASES; FERRITINS; GREECE; HEPATITIS C, CHRONIC; HUMANS; HYPERSPLENISM; INFLAMMATION; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MYOCARDIUM; SPLENECTOMY; TRANSFERRIN; YOUNG ADULT;

EID: 72449151347     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01342.x     Document Type: Article

References (23)

1. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol 2007 82 : 255 265.
2. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001 38 : 30 6.
3. Vichinsky E, Butensky E, Fung E, Hudes M, Theil E, Ferrell L, Williams R, Louie L, Lee PD, Harmatz P. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005 80 : 70 4.
4. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004 103 : 1934 1936.
5. Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A, Loutradi A, Loukopoulos D. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol 2004 126 : 736 742.
6. Karam LB, Disco D, Jackson SM, Lewin D, McKie V, Baker RD, Baker SS, Laver JH, Nietert PJ, Abboud MR. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatr Blood Cancer 2008 50 : 62 5.
7. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978 40 : 255 263.
8. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003 101 : 4632 4639.
9. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005 18 : 277 287.
10. Wang WC, Ahmed N, Hanna M. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias. J Pediatr 1986 108 : 552 557.
11. Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, Porter J, Evans P, Vichinsky E, Harmatz P. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006 135 : 254 263.
12. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004 104 : 1504 1510.
13. Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, Palmor H, Tamary H. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol 2008 83 : 366 370.
14. Blum A, Peleg A, Merei M, Tatour I, Khazim K, Simsolo C, Yegane S. High sensitive C-reactive protein (hs-CRP) level in patients with sickle cell anemia. Haema 2005 8 : 462 464.
15. Ghoti H, Goiten O, Konen E, Koren A, Levin C, Berebi A, Stark P, Rachmilewitz E. T2*MRI Provides no Evidence for Myocardial and Pancreatic Iron Overload in Multitransfused Patients with Sickle/ß Thalassemia. San Diego, CA : Am Society of Hematology, 2008.
16. Piga A, Longo F, Duca L, Roggero S, Vinciguerra T, Calabrese R, Hershko C, Cappellini MD. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009 84 : 29 33.
17. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996 88 : 705 713.
18. al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. Br J Haematol 1992 82 : 431 436.
19. Pippard M. Secondary Iron Overload, Iron Metabolism in Health and Disease. Brock JH, Pippard MJ, Powel LW, eds. London : WB Saunders 1994 : 272 300.
20. Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, Moats R, Coates TD. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci 2005 1054 : 386 395.
21. Jenkins ZA, Hagar W, Bowlus CL, Johansson HE, Harmatz P, Vichinsky EP, Theil EC. Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol 2007 24 : 237 243.
22. Weizer-Stern O, Adamsky K, Amariglio N, et al. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br J Haematol 2006 135 : 129 138.
23. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007 13 : 1096 1101.